Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Dr. Reddy's Laboratories Ltd RDY

Headquartered in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company's sales are well dispersed across North America, India, and other emerging markets.


Recent & Breaking News (NYSE:RDY)

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity

Business Wire September 7, 2022

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.

Business Wire July 29, 2022

Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

Business Wire July 27, 2022

Dr. Reddy's Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Business Wire July 22, 2022

Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market

Business Wire July 8, 2022

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx

Business Wire July 5, 2022

Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma

Business Wire June 24, 2022

Eton Pharmaceuticals Announces Sale of Hospital Products

GlobeNewswire June 24, 2022

Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market

Business Wire June 14, 2022

Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market

Business Wire May 27, 2022

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market

Business Wire May 24, 2022

Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market

Business Wire April 20, 2022

Dr. Reddy's Laboratories Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market

Business Wire April 5, 2022

Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany

Business Wire April 1, 2022

Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market

Business Wire February 9, 2022

Dr. Reddy's Laboratories Enters Into Definitive Agreement to Acquire German Medical Cannabis Firm Nimbus Health GmbH

Business Wire February 3, 2022

Dr. Reddy's Included in S&P Global's Sustainability Yearbook for the 2nd Year and Bloomberg Gender-Equality Index for the 5th Year in a Row

Business Wire February 2, 2022

Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market

Business Wire December 9, 2021

Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market

Business Wire December 9, 2021

Prestige BioPharma and Dr. Reddy's announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia

Business Wire December 8, 2021